Shire Reports Positive Results From Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Ca...

PHILADELPHIA, April 28, 2011 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP,NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced positive results from a signal-finding study of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules (CII) assessing its effect in a prospective examination of adults with negative symptom predominant schizophrenia. This study met its pre-defined primary end points.